Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study

seekingalpha08-12

Marker Therapeutics (NASDAQ:MRKR) stock rose 7% after the biotech company said it has been awarded a $2M grant by the National Institutes of Health to support a Phase 1 study of its drug candidate MT-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2458982620?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1327693610/image_1327693610.jpg","is_english":true,"pubTime":"2024-08-12 22:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2458982620","market":"fut","top_or_hot":-1,"title":"Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study","media":"seekingalpha","content":"<div>\n<p>Marker Therapeutics (NASDAQ:MRKR) stock rose 7% after the biotech company said it has been awarded a $2M grant by the National Institutes of Health to support a Phase 1 study of its drug candidate MT-...</p>\n\n<a href=\"https://seekingalpha.com/news/4138667-marker-therapeutics-gets-2m-nih-grant-for-mt-601-phase-1-study\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Marker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMarker Therapeutics gets $2M NIH grant for MT-601 Phase 1 study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-12 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4138667-marker-therapeutics-gets-2m-nih-grant-for-mt-601-phase-1-study><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Marker Therapeutics (NASDAQ:MRKR) stock rose 7% after the biotech company said it has been awarded a $2M grant by the National Institutes of Health to support a Phase 1 study of its drug candidate MT-...</p>\n\n<a href=\"https://seekingalpha.com/news/4138667-marker-therapeutics-gets-2m-nih-grant-for-mt-601-phase-1-study\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4561","symbol_name":"索罗斯持仓","start_time":0,"source_url":"https://seekingalpha.com/news/4138667-marker-therapeutics-gets-2m-nih-grant-for-mt-601-phase-1-study","article_id":"2458982620","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1327693610/image_1327693610.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2458982620","pubTimestamp":1723474543,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Marker Therapeutics  stock rose 7% after the biotech company said it has been awarded a $2M grant by the National Institutes of Health to support a Phase 1 study of its drug candidate MT-601 in the treatment of non-Hodgkin’s lymphoma, or NHL.The study will evaluate the safety and efficacy of MT-601 in the treatment of patients with relapsed NHL, including those previously treated with anti-CD19 CAR-T cell therapy, according to a statement.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4561":"索罗斯持仓","MRKR":"Marker Therapeutics, Inc.","BK4006":"钢铁","BK4139":"生物科技","LENZ":"Therapeutics","MT":"安赛乐米塔尔"},"translate_title":"Marker Therapeutics获得NIH 200万美元资助用于MT-601 1期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MRKR":1,"MT":1},"content_text":"Marker Therapeutics (NASDAQ:MRKR) stock rose 7% after the biotech company said it has been awarded a $2M grant by the National Institutes of Health to support a Phase 1 study of its drug candidate MT-601 in the treatment of non-Hodgkin’s lymphoma, or NHL.\nThe study will evaluate the safety and efficacy of MT-601 in the treatment of patients with relapsed NHL, including those previously treated with anti-CD19 CAR-T cell therapy, according to a statement.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2458982620"}